Dialysis patients and cardiovascular problems: can technology solve the complex equation?

被引:13
作者
Ronco, Claudio [1 ]
Tetta, Ciro [1 ]
机构
[1] St Bortolo Hosp, Dept Nephrol, I-36100 Vicenza, Italy
关键词
cardiovascular complications; HDF; hemodialysis; online hemodiafiltration;
D O I
10.1586/17434440.2.6.681
中图分类号
R318 [生物医学工程];
学科分类号
0831 [生物医学工程];
摘要
Patients with end-stage kidney disease undergoing chronic hemodialysis present higher mortality rates compared with the general population. Once patients are on hemodialysis, the risk of cardiovascular death is approximately 30-times higher than the general population, and still remains 10- to 20-times higher after stratification for age, gender and presence of diabetes. Approximately half of patient deaths on dialysis are attributed to cardiovascular causes, including coronary heart disease, cerebrovascular disease, peripheral vascular disease and heart failure. The cardiovascular burden of the hemodialysis patient arises from three different sources: risks inherent to the patient and the uremic syndrome, traditional risk factors and risk factors related to the dialysis therapy. Based on these considerations and the fact that several aspects of the dialysis procedure can cause either a cardiovascular burden or modify the burden already present, new technologies should be directed towards the approach of a possible 'cardioprotective dialysis therapy'. This approach may significantly contribute new techniques and new dialysis machines. Born to make dialysis easy and safe, the new machines feature several options that make monitoring and online hemodiafiltration a simple routine. These and other features could make dialysis better tolerated and more efficient in protecting from fatal cardiovascular events.
引用
收藏
页码:681 / 687
页数:7
相关论文
共 51 条
[1]
Ahrenholz PG, 2004, CLIN NEPHROL, V62, P21
[2]
Ayli D, 2004, J NEPHROL, V17, P701
[3]
Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study [J].
Bammens, B ;
Evenepoel, P ;
Verbeke, K ;
Vanrenterghem, Y .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (02) :278-285
[4]
BAMMENS B, 2003, J AM SOC NEPHROL, V14, P911
[5]
Barrett BJ, 2002, DIALYSIS TRANSPLANT, V31, P155
[6]
Boer W., 2002, Nephrology Dialysis Transplantation, V17, P127
[7]
Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients [J].
Bologa, RM ;
Levine, DM ;
Parker, TS ;
Cheigh, JS ;
Serur, D ;
Stenzel, KH ;
Rubin, AL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) :107-114
[8]
Removal of uraemic plasma factor(s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells [J].
Bonomini, M ;
Ballone, E ;
Di Stante, S ;
Bucciarelli, T ;
Dottori, S ;
Arduini, A ;
Urbani, A ;
Sirolli, V .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (01) :68-74
[9]
Dialysis membranes today [J].
Bowry, SK .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2002, 25 (05) :447-460
[10]
Potential cardiovascular risk factors in chronic kidney disease:: AGEs, total homocysteine and metabolites, and the C-reactive protein [J].
Busch, M ;
Franke, S ;
Müller, A ;
Wolf, M ;
Gerth, J ;
Ott, U ;
Niwa, T ;
Stein, G .
KIDNEY INTERNATIONAL, 2004, 66 (01) :338-347